Bladder Cancer And Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now approved in earlier treatment settings. Keytruda is now poised to become the standard of care in the first-line setting in combination with the antibody-drug conjugate Padcev (Seagen / Astellas) in cisplatin-ineligible patients. In the high-risk BCG-unresponsive population, Adstiladrin (Ferring Pharmaceuticals) is the first gene therapy available to treat bladder cancer in the United States. The approval of Bavencio (Merck KGaA / Pfizer) as maintenance therapy for first-line locally advanced or metastatic urothelial carcinoma highlights the expanded use of immune checkpoint inhibitors in all lines of therapy across the geographies covered. The initial entry of antibody-drug conjugates Padcev and Trodelvy (Gilead) has diversified the treatment paradigm for previously treated advanced or metastatic disease. Several new therapies and combinations, anticipated to be approved by 2032, will only intensify the competition in this market.
Question answered
What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer and UTUC populations, and how will drug-treatment rates change over time?
How is bladder cancer and upper tract urothelial carcinoma currently treated, and how do their treatment options differ? What are the key advantages and disadvantages of existing drugs? What is the expected market impact of recent approvals?
Which of the emerging therapies are viewed as most promising, and what sales / uptake could they secure in the bladder cancer and UTUC market?
What are the key market drivers and constraints, and how will the market evolve over the 10-year forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Bladder Cancer And Upper Tract Urothelial Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
Key findings
Bladder Cancer and UTUC - Key Findings
Key updates
July 2023
April 2023
Q4 2022
October 2022
Q2 2022
June 2022
May 2022
April 2022
Q1 2022
March 2022
February 2022
January 2022
Market outlook
Key findings
Market share of drug classes for bladder cancer and UTUC: 2021
Market share of drug classes for bladder cancer and UTUC: 2031
Drug-treatable population share and major-market sales share in bladder cancer and UTUC: 2021
Drug-treatable population share and major-market sales share in bladder cancer and UTUC: 2031
Population positioning of therapies in bladder cancer and UTUC: United States
Population positioning of therapies in bladder cancer and UTUC: Europe
Population positioning of therapies in bladder cancer and UTUC: Japan
Bladder cancer and UTUC SWOT analysis
Market drivers and constraints
What factors are driving the market for bladder cancer and UTUC?
What factors are constraining the market for bladder cancer and UTUC?
Major market sales of key therapies (excluding immune checkpoint inhibitors) in the bladder cancer and UTUC market: 2021-2031
Major market sales of immune checkpoint inhibitors in the bladder cancer market and UTUC: 2021-2031
Segment-specific trends
Patient-share dynamics for key treatments for non-muscle-invasive bladder cancer in the United States: 2021-2031
Patient-share dynamics for key treatments for non-muscle-invasive UTUC in the United States: 2021-2031
Patient share dynamics for key treatments for non-muscle-invasive bladder cancer in Europe: 2021-2031
Patient-share dynamics of key treatments for localized and resectable locally advanced muscle-invasive bladder cancer in the major markets: 2021-2031
Patient-share dynamics of key treatments for localized and resectable locally advanced muscle-invasive UTUC in the major markets: 2021-2031
Patient-share dynamics of key treatments in first-line unresectable locally advanced or metastatic bladder cancer and UTUC in the United States: 2021-2031
Patient-share dynamics of key treatments for first-line unresectable locally advanced or metastatic bladder cancer and UTUC in Europe: 2021-2031
Patient-share dynamics of key treatments for first-line unresectable locally advanced or metastatic bladder cancer and UTUC in Japan: 2021-2031
Patient-share dynamics of key treatments for second-line metastatic bladder cancer and UTUC in the major markets: 2021-2031
Patient-share dynamics of key treatments for third-line metastatic bladder cancer and UTUC in the major markets: 2021-2031
Forecast
Market forecast downloads
Market forecast assumptions
Market forecast dashboard
Etiology and pathophysiology
Disease overview
Disease pathophysiology
Anatomy of the urinary system
Bladder cancer and upper tract urothelial carcinoma pathology
Staging and classification
Definitions of the TNM staging system for bladder cancer and UTUC
AJCC / UICC TNM staging classification system for bladder cancer and UTUC
Key pathways and drug targets
Key pathways and drug targets for bladder cancer and upper tract urothelial carcinoma
Epidemiology
Key findings
Epidemiology populations
Disease definition
Methods bladder cancer
Sources used for diagnosed incidence of bladder cancer
Diagnosed incident cases of bladder cancer: 2021-2031
Methods upper tract urothelial carcinoma
Diagnosed incident cases of upper tract urothelial carcinoma: 2021-2031
Disease definition
Methods bladder cancer
Sources used for stage distribution of bladder cancer
Methods and sources used for upper tract urothelial carcinoma
Diagnosed incident cases of bladder cancer by stage: 2021-2031
Diagnosed incident cases of bladder cancer by muscle-invasiveness at diagnosis: 2021-2031
Diagnosed incident cases of upper tract urothelial carcinoma by stage: 2021-2031
Definition
Methods
Sources used for locally recurrent incident cases of bladder cancer and upper tract urothelial carcinoma
Locally recurrent incident cases of bladder cancer: 2021-2031
Locally recurrent incident cases of upper tract urothelial carcinoma: 2021-2031
Definition
Methods
Sources used for intravesical recurrent incident cases of upper tract urothelial carcinoma
Intravesical recurrent incident cases of upper tract urothelial carcinoma: 2021-2031
Definition
Methods
Sources used for metastatic recurrent incident cases of bladder cancer and upper tract urothelial carcinoma
Metastatic recurrent incident cases of bladder cancer: 2021-2031
Metastatic recurrent incident cases of upper tract urothelial carcinoma: 2021-2031
Bladder cancer and upper tract urothelial carcinoma patient flow
Sources used for drug-treatable populations of bladder cancer and UTUC
Drug-treatable cases of bladder cancer and UTUC: 2021-2031
Drug-treated cases of bladder cancer and UTUC: 2021-2031
Current treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for bladder cancer and UTUC
Key current therapies
Overview
Mechanism of action of key current drug classes used for bladder cancer and UTUC
Current treatments used for bladder cancer and UTUC
Market events impacting the use of key current therapies in bladder cancer and UTUC
Key results from select clinical trials investigating Tecentriq for the treatment of bladder cancer and UTUC
Ongoing clinical development of Tecentriq
Key ongoing clinical trials of Tecentriq in the treatment of bladder cancer and UTUC
Expert insight: Tecentriq
Key results from select clinical trials investigating Opdivo for the treatment of bladder cancer and UTUC
Ongoing clinical development of Opdivo
Key ongoing clinical trials of Opdivo in the treatment of bladder cancer and UTUC
Expert insight: Opdivo
Key results from select clinical trials investigating Keytruda for the treatment of bladder cancer and UTUC
Ongoing clinical development of Keytruda
Key ongoing clinical trials of Keytruda in the treatment of bladder cancer and UTUC
Expert insight: Keytruda
Key results from select clinical trials investigating Bavencio for the treatment of bladder cancer and UTUC
Ongoing clinical development of Bavencio
Key ongoing clinical trials of Bavencio in the treatment of bladder cancer and UTUC
Expert insight: Bavencio
Balversa
Key results from select clinical trials investigating Balversa for the treatment of bladder cancer and UTUC
Ongoing clinical development of Balversa
Key ongoing clinical trials of Balversa in the treatment of bladder cancer and UTUC
Expert insight: Balversa
Key results from select clinical trials investigating Padcev for the treatment of bladder cancer and UTUC
Ongoing clinical development of Padcev
Key ongoing clinical trials of Padcev in the treatment of bladder cancer and UTUC
Expert insight: Padcev
Trodelvy
Key results from select clinical trials investigating Trodelvy for the treatment of bladder cancer and UTUC
Ongoing clinical development of Trodelvy
Key ongoing clinical trials of Trodelvy in the treatment of bladder cancer and UTUC
Expert insight: Trodelvy
Jelmyto
Key results from select clinical trials investigating Jelmyto for the treatment of bladder cancer and UTUC
Ongoing clinical development of Jelmyto
Key ongoing clinical trials of Jelmyto in the treatment of bladder cancer and UTUC
Expert insight: Jelmyto
Key results from select clinical trials investigating Adstiladrin for the treatment of bladder cancer and UTUC
Ongoing clinical development of Adstiladrin
Key ongoing clinical trials of Adstiladrin in the treatment of bladder cancer and UTUC
Expert insight: Adstiladrin
Medical practice
Non-muscle-invasive bladder cancer and UTUC
Localized and resectable locally advanced bladder cancer and UTUC
First-line unresectable locally advanced or metastatic bladder cancer and UTUC
Second- and third-line metastatic bladder cancer and UTUC
Patient characteristics influencing drug selection in bladder cancer and UTUC
Region-specific treatment practices
Treatment decision tree for bladder cancer and UTUC: United States
Treatment decision tree for bladder cancer and UTUC: Europe
Treatment decision tree for bladder cancer and UTUC: Japan
Unmet need overview
Attainment of unmet needs
Current and future attainment of unmet needs in bladder cancer and UTUC
Top unmet bladder cancer and upper tract urothelial carcinoma: current and future attainment
Expert insights: unmet need in bladder cancer and upper tract urothelial carcinoma
Drug pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging therapies
Key findings
Key emerging therapies
Key therapies in development for bladder cancer and UTUC
Estimated market authorization dates of key emerging therapies for the treatment of bladder cancer and UTUC
Key results from select clinical trials investigating sasanlimab for the treatment of bladder cancer and UTUC
Analysis of the clinical development program for sasanlimab
Key ongoing clinical trials of sasanlimab in the treatment of bladder cancer and UTUC
Expert insight: sasanlimab
Expectations for market authorization and sales opportunity of sasanlimab in bladder cancer and UTUC
Key results from select clinical trials investigating cetrelimab for the treatment of bladder cancer and UTUC
Analysis of the clinical development program for cetrelimab
Key ongoing clinical trials of cetrelimab in the treatment of bladder cancer and UTUC
Expert insight: Cetrelimab
Expectations for market authorization and sales opportunity of cetrelimab in bladder cancer and UTUC
Key results from select clinical trials investigating Imfinzi for the treatment of bladder cancer and UTUC
Analysis of the clinical development program for Imfinzi
Key ongoing clinical trials of Imfinzi in the treatment of bladder cancer and UTUC
Expert insight: Imfinzi
Expectations for market authorization and sales opportunity of Imfinzi in bladder cancer and UTUC
Key results from select clinical trials investigating cretostimogene grenadenorepvec in bladder cancer and UTUC
Analysis of the clinical development program for cretostimogene grenadenorepvec
Key ongoing clinical trials of cretostimogene grenadenorepvec in the treatment of bladder cancer and UTUC
Expert insight: cretostimogene grenadenorepvec
Expectations for market authorization and sales opportunity of cretostimogene grenadenorepvec in bladder cancer and UTUC
Key results from select clinical trials investigating Anktiva for the treatment of bladder cancer and UTUC
Analysis of the clinical development program for Anktiva
Key ongoing clinical trials of Anktiva in bladder cancer and UTUC
Expectations for market authorization and sales opportunity of Anktiva in bladder cancer and UTUC
Key results from select clinical trials investigating TAR-200 for the treatment of bladder cancer and UTUC
Analysis of the clinical development program for TAR-200
Key ongoing clinical trials of TAR-200 in the treatment of bladder cancer and UTUC
Expert insight: TAR-200
Expectations for market authorization and sales opportunity of TAR-200 in bladder cancer and UTUC
Key results from select clinical trials investigating UGN-102 for the treatment of bladder cancer and UTUC
Analysis of the clinical development program for UGN-102
Key ongoing clinical trials of UGN-102 in the treatment of bladder cancer and UTUC
Expert insight: UGN-102
Expectations for market authorization and sales opportunity of UGN-102 in bladder cancer and UTUC
Key results from select clinical trials investigating truseltiq for the treatment of bladder cancer and UTUC
Analysis of the clinical development program for Truseltiq
Key ongoing clinical trials of Truseltiq in the treatment of Bladder cancer and UTUC
Expert insight: Truseltiq
Expectations for market authorization and sales opportunity of Truseltiq in Bladder cancer and UTUC
Early-phase pipeline analysis
Select compounds in early-phase development for bladder cancer and UTUC
Access & reimbursement overview
Region-specific reimbursement practices
Key market access considerations in bladder cancer and upper tract urothelial carcinoma: United States
General reimbursement environment: United States
Key market access considerations in bladder cancer and UTUC: EU5
General reimbursement environment: EU5
Key market access considerations in bladder cancer and UTUC: Japan
General reimbursement environment: Japan
Appendix
Bladder cancer and UTUC bibliography
Liseth Parra
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.
Marcos Fernu00e1ndez Alfara
Marcos Fernández Alfara, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Fernández has extensive experience in oncology, with a focus on novel immunotherapies for solid tumors. As part of his doctorate, he developed new strategies to boost immune responses against cancer cells. He obtained his master of science degree in cancer and stem cells from Utrecht University and his doctorate in biomedicine from the Institute for Research in Biomedicine at Barcelona University.